Addex Therapeutics Ltd. (NASDAQ: ADXN)

Addex Therapeutics Ltd., a clinical-stage pharmaceutical company based in Switzerland, operates under the ticker symbol ADXN. The company specializes in the development of orally available small molecule drug candidates, with a focus on allosteric modulation. This innovative approach targets specific receptors and proteins in the body, setting Addex apart in the pharmaceutical industry.

Addex's primary business activities involve the development of a pipeline of proprietary clinical and preclinical stage drug candidates. These candidates are being developed both internally and through partnerships with other companies. Addex's expertise in allosteric modulation has been recognized and validated through its partnerships with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and Indivior PLC.

The company generates revenue through the development of these drug candidates. Its primary products include ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy, and dipraglurant, a selective, orally active small molecule drug product that acts as a metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM). These products are being developed for various indications, including Parkinson's disease levodopa-induced dyskinesia (PD-LID), post-stroke sensorimotor recovery, substance use disorder, and chronic cough.

Addex's competitive position within the pharmaceutical industry is strengthened by its leadership in allosteric modulation and its strong pipeline of proprietary clinical and preclinical stage drug candidates. The company's key competitors include multinational and specialized pharmaceutical companies developing drugs for similar indications, such as racetams, benzodiazepines, carboxamides, GABA analogs, and perampanel.

In terms of its customers, Addex Therapeutics partners with pharmaceutical companies seeking to develop and commercialize innovative drug products. The company has established partnerships with Janssen Pharmaceuticals, Inc. and Indivior PLC for the development and commercialization of its drug candidates.

Addex Therapeutics' product portfolio includes a range of brand names and trade names. Its lead partnered drug candidate, ADX71149, is a key product, while dipraglurant leads its wholly owned drug candidate portfolio. The company also has a GABAB positive allosteric modulator (PAM) program for the treatment of substance use disorder and chronic cough, licensed to Indivior PLC.